Aurinia Names CEO
This article was originally published in Scrip
Aurinia Pharmaceuticals Inc. has appointed Charles Rowland CEO, replacing Stephen Zaruby who will be resigning as the company's CEO and from its board of directors. Rowland was vice president and chief financial officer (CFO) of ViroPharma Inc. until it was acquired by Shire PLC. in 2014. Prior to this, he held various leadership positions at biotech and pharma companies and most recently was interim co-CEO, executive vice president, CFO for Endo Pharmaceuticals Inc. Previously Rowland held positions at Biovail Corp., Breakaway Technologies Inc., Pharmacia Corp., Novartis AG and Bristol-Myers Squibb.
You may also be interested in...
Following consultations with the FDA, Canada's Aurinia Pharmaceuticals plans to run a single Phase III trial for voclosporin in lupus nephritis and then proceed to filing an NDA.
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.